Overview
Analgesic Efficacy of Maxigesic in Breast Cancer Surgery
Status:
Recruiting
Recruiting
Trial end date:
2025-02-26
2025-02-26
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
The present study aims to find a perioperative analgesic method that provides sufficient analgesia while reducing immune compromise in cancer surgery. This study is to investigate the analgesic effect and safety of Maxigesic inj. (a combination of acetaminophen 1000 mg and ibuprofen 300 mg), which is added to opioid-based IV-PCA in patients undergoing breast cancer surgery.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Yonsei University
Criteria
Inclusion Criteria:- Patient aged 20 to 70 years with ASA classification 1 to 3 undergoing breast cancer
surgery (cancer resection or reconstruction)
Exclusion Criteria:
- ASA classification 4/ allergy to acetaminophen, NSAIDs, opioid/ severe liver or renal
dysfunction/ pregnancy